• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[心血管疾病预防建议。PAPPS 2024主题更新]

[Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].

作者信息

Orozco-Beltrán Domingo, Brotons-Cuixart Carlos, Banegas José R, Gil-Guillen Vicente F, Cebrián-Cuenca Ana M, Martín-Rioboó Enrique, Jordá-Baldó Ariana, Vicuña Johanna, Navarro-Pérez Jorge

机构信息

Medicina Familiar y Comunitaria, Unidad de Investigación CS Cabo Huertas, Departamento San Juan de Alicante. Departamento de Medicina Clínica. Centro de Investigación en Atención Primaria. Universidad Miguel Hernández, San Juan de Alicante, España.

Medicina Familiar y Comunitaria. Institut de Recerca Sant Pau (IR SANT PAU). Equipo de Atención Primaria Sardenya, Barcelona, España.

出版信息

Aten Primaria. 2024 Nov;56 Suppl 1(Suppl 1):103123. doi: 10.1016/j.aprim.2024.103123.

DOI:10.1016/j.aprim.2024.103123
PMID:39613355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11705607/
Abstract

The recommendations of the semFYC's Program for Preventive Activities and Health Promotion (PAPPS) for the prevention of vascular diseases (VD) are presented. New in this edition are new sections such as obesity, chronic kidney disease and metabolic hepatic steatosis, as well as a 'Don't Do' section in the different pathologies treated. The sections have been updated: epidemiological review, where the current morbidity and mortality of CVD in Spain and its evolution as well as the main risk factors are described; vascular risk (VR) and recommendations for the calculation of CV risk; main risk factors such as arterial hypertension, dyslipidemia and diabetes mellitus, describing the method for their diagnosis, therapeutic objectives and recommendations for lifestyle measures and pharmacological treatment; indications for antiplatelet therapy, and recommendations for screening of atrial fibrillation, and recommendations for management of chronic conditions. The quality of testing and the strength of the recommendation are included in the main recommendations.

摘要

本文介绍了西班牙心血管病学会预防活动与健康促进项目（PAPPS）针对血管疾病（VD）预防的建议。此版本的新内容包括肥胖、慢性肾脏病和代谢性肝脂肪变性等新章节，以及在不同治疗病症中设置的“不要做”章节。各章节已更新：流行病学综述，描述了西班牙心血管疾病当前的发病率和死亡率及其演变情况以及主要风险因素；血管风险（VR）和心血管风险计算建议；主要风险因素，如动脉高血压、血脂异常和糖尿病，阐述了其诊断方法、治疗目标以及生活方式措施和药物治疗建议；抗血小板治疗指征、心房颤动筛查建议以及慢性病管理建议。主要建议中包含了检测质量和推荐强度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/bd310c42ce7c/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/47f708d48b19/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/dc71174575f4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/7cdc19f37008/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/9c278d74e43a/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/61ee4db136d1/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/387fcaebc1f8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/8cf0004e3792/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/8c58d126c0ab/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/6d78dc28e3ef/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/bd310c42ce7c/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/47f708d48b19/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/dc71174575f4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/7cdc19f37008/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/9c278d74e43a/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/61ee4db136d1/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/387fcaebc1f8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/8cf0004e3792/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/8c58d126c0ab/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/6d78dc28e3ef/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12da/11705607/bd310c42ce7c/gr10.jpg

相似文献

1
[Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].[心血管疾病预防建议。PAPPS 2024主题更新]
Aten Primaria. 2024 Nov;56 Suppl 1(Suppl 1):103123. doi: 10.1016/j.aprim.2024.103123.
2
[Cardiovascular preventive recommendations. PAPPS 2022 thematic updates. Working groups of the PAPPS].[心血管预防建议。PAPPS 2022主题更新。PAPPS工作组]
Aten Primaria. 2022 Oct;54 Suppl 1(Suppl 1):102444. doi: 10.1016/j.aprim.2022.102444.
3
[Cardiovascular preventive recommendations. PAPPS 2020 update].[心血管预防建议。PAPPS 2020更新版]
Aten Primaria. 2020 Nov;52 Suppl 2(Suppl 2):5-31. doi: 10.1016/j.aprim.2020.08.002.
4
[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice].[2016年欧洲临床实践心血管疾病预防指南的西班牙文改编版]
Hipertens Riesgo Vasc. 2017 Jan-Mar;34(1):24-40. doi: 10.1016/j.hipert.2016.11.006. Epub 2016 Dec 23.
5
Clinical decisions in patients with diabetes and other cardiovascular risk factors. A statement of the Spanish Society of Internal Medicine.糖尿病及其他心血管危险因素患者的临床决策。西班牙内科协会声明。
Rev Clin Esp (Barc). 2014 May;214(4):209-15. doi: 10.1016/j.rce.2013.12.014. Epub 2014 Mar 3.
6
[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice].《2016年欧洲临床实践心血管疾病预防指南》的西班牙文改编版
Gac Sanit. 2017 May-Jun;31(3):255-268. doi: 10.1016/j.gaceta.2016.12.007. Epub 2017 Mar 11.
7
Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.西班牙跨学科血管预防委员会关于更新的欧洲心血管预防指南的声明。
Clin Investig Arterioscler. 2021 Mar-Apr;33(2):85-107. doi: 10.1016/j.arteri.2020.11.004. Epub 2021 Jan 22.
8
[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice].[《2016年欧洲临床实践心血管疾病预防指南》的西班牙文改编版]
Semergen. 2017 May-Jun;43(4):295-311. doi: 10.1016/j.semerg.2016.11.012. Epub 2017 May 19.
9
Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice.《2016年欧洲临床实践心血管疾病预防指南》的西班牙语译本
Clin Investig Arterioscler. 2017 Mar-Apr;29(2):69-85. doi: 10.1016/j.arteri.2016.11.004. Epub 2017 Feb 4.
10
Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018).糖尿病与心血管风险：西班牙糖尿病学会糖尿病与心血管疾病工作组建议更新（2018年）
Clin Investig Arterioscler. 2018 May-Jun;30(3):137-153. doi: 10.1016/j.arteri.2018.03.002. Epub 2018 May 10.

引用本文的文献

1
[Continuous vascular risk with high blood pressure levels. Commentary on vascular and HTA PAPPS 2024 recommendations].[高血压水平下的持续血管风险。关于血管和高血压防治行动规划与预防战略（PAPPS）2024建议的评论]
Aten Primaria. 2025 Apr;57(4):103231. doi: 10.1016/j.aprim.2025.103231. Epub 2025 Feb 12.

本文引用的文献

1
Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care.2型糖尿病患者的血糖和体重控制：一项基层医疗中的真实世界观察性研究。
Prim Care Diabetes. 2025 Feb;19(1):7-14. doi: 10.1016/j.pcd.2024.12.002. Epub 2024 Dec 31.
2
2024 ESC Guidelines for the management of elevated blood pressure and hypertension.2024年欧洲心脏病学会高血压管理指南
Eur Heart J. 2024 Oct 7;45(38):3912-4018. doi: 10.1093/eurheartj/ehae178.
3
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
司美格鲁肽处方治疗患者发生非动脉炎性前部缺血性视神经病变的风险。
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
4
2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension.2024年欧洲高血压学会动脉高血压管理临床实践指南
Eur J Intern Med. 2024 Aug;126:1-15. doi: 10.1016/j.ejim.2024.05.033. Epub 2024 Jun 24.
5
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
6
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).一项2型糖尿病强化血糖控制随机对照试验的试验后监测，时间从10年延长至24年（英国前瞻性糖尿病研究91）
Lancet. 2024 Jul 13;404(10448):145-155. doi: 10.1016/S0140-6736(24)00537-3. Epub 2024 May 18.
7
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.2 型糖尿病患者二线口服降糖药物治疗的疗效比较：利用常规收集的健康数据模拟目标试验。
BMJ. 2024 May 8;385:e077097. doi: 10.1136/bmj-2023-077097.
8
Numerical values and impact of hypertension in Spain.西班牙的高血压数值和影响。
Rev Esp Cardiol (Engl Ed). 2024 Sep;77(9):767-778. doi: 10.1016/j.rec.2024.03.011. Epub 2024 May 1.
9
Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024;47(Suppl. 1):S158-S178.勘误。9. 血糖治疗的药理学方法：2024年糖尿病护理标准。《糖尿病护理》2024年；47（增刊1）：S158 - S178。
Diabetes Care. 2024 Jul 1;47(7):1238. doi: 10.2337/dc24-er07a.
10
Enhancing clinical decision-making: Optimizing ChatGPT's performance in hypertension care.增强临床决策：优化ChatGPT在高血压护理中的表现。
J Clin Hypertens (Greenwich). 2024 May;26(5):588-593. doi: 10.1111/jch.14822. Epub 2024 Apr 22.